PL394618A1 - Przeciwnowotworowe bialko fuzyjne - Google Patents

Przeciwnowotworowe bialko fuzyjne

Info

Publication number
PL394618A1
PL394618A1 PL394618A PL39461811A PL394618A1 PL 394618 A1 PL394618 A1 PL 394618A1 PL 394618 A PL394618 A PL 394618A PL 39461811 A PL39461811 A PL 39461811A PL 394618 A1 PL394618 A1 PL 394618A1
Authority
PL
Poland
Prior art keywords
fusion protein
domain
sequence
terminus
functional fragment
Prior art date
Application number
PL394618A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Piotr Kamil Rózga
Urszula Marta Szawłowska
Krzysztof Kazimierz Lemke
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL394618A priority Critical patent/PL394618A1/pl
Priority to BR112013025975A priority patent/BR112013025975A2/pt
Priority to CN201280019018.5A priority patent/CN103562220A/zh
Priority to EP12715691.7A priority patent/EP2699592A2/en
Priority to EA201391546A priority patent/EA201391546A1/ru
Priority to SG2013070826A priority patent/SG193925A1/en
Priority to CA2832152A priority patent/CA2832152A1/en
Priority to PH1/2013/501970A priority patent/PH12013501970A1/en
Priority to JP2014505636A priority patent/JP2014513943A/ja
Priority to NZ617353A priority patent/NZ617353B2/en
Priority to US14/008,234 priority patent/US20140031283A1/en
Priority to KR1020137029312A priority patent/KR20140019828A/ko
Priority to AU2012244654A priority patent/AU2012244654A1/en
Priority to PCT/EP2012/057219 priority patent/WO2012143477A2/en
Priority to MX2013012242A priority patent/MX2013012242A/es
Publication of PL394618A1 publication Critical patent/PL394618A1/pl
Priority to ZA2013/08597A priority patent/ZA201308597B/en
Priority to IL228731A priority patent/IL228731A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL394618A 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne PL394618A1 (pl)

Priority Applications (17)

Application Number Priority Date Filing Date Title
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne
PH1/2013/501970A PH12013501970A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
US14/008,234 US20140031283A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
EP12715691.7A EP2699592A2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
EA201391546A EA201391546A1 (ru) 2011-04-19 2012-04-19 Противораковый слитый белок
SG2013070826A SG193925A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
CA2832152A CA2832152A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
BR112013025975A BR112013025975A2 (pt) 2011-04-19 2012-04-19 proteína de fusão anticancerígena
JP2014505636A JP2014513943A (ja) 2011-04-19 2012-04-19 抗がん融合タンパク質
NZ617353A NZ617353B2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
CN201280019018.5A CN103562220A (zh) 2011-04-19 2012-04-19 抗癌融合蛋白
KR1020137029312A KR20140019828A (ko) 2011-04-19 2012-04-19 항암 융합 단백질
AU2012244654A AU2012244654A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
PCT/EP2012/057219 WO2012143477A2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
MX2013012242A MX2013012242A (es) 2011-04-19 2012-04-19 Proteina de fusion anticancerigena.
ZA2013/08597A ZA201308597B (en) 2011-04-19 2013-11-15 Anticancer fusion protein
IL228731A IL228731A0 (en) 2011-04-19 2013-11-21 anticancer fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne

Publications (1)

Publication Number Publication Date
PL394618A1 true PL394618A1 (pl) 2012-10-22

Family

ID=45990644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne

Country Status (16)

Country Link
US (1) US20140031283A1 (pl)
EP (1) EP2699592A2 (pl)
JP (1) JP2014513943A (pl)
KR (1) KR20140019828A (pl)
CN (1) CN103562220A (pl)
AU (1) AU2012244654A1 (pl)
BR (1) BR112013025975A2 (pl)
CA (1) CA2832152A1 (pl)
EA (1) EA201391546A1 (pl)
IL (1) IL228731A0 (pl)
MX (1) MX2013012242A (pl)
PH (1) PH12013501970A1 (pl)
PL (1) PL394618A1 (pl)
SG (1) SG193925A1 (pl)
WO (1) WO2012143477A2 (pl)
ZA (1) ZA201308597B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
CN106132986B (zh) * 2015-03-02 2019-08-30 成都华创生物技术有限公司 TRAIL穿膜肽样突变体MuR5、制备方法及应用
WO2017066963A1 (zh) * 2015-10-22 2017-04-27 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
US12344645B2 (en) 2017-03-29 2025-07-01 Polaris Group Protein conjugates
US20260226184A1 (en) * 2023-01-26 2026-08-06 Dana-Farber Cancer Institute, Inc. Developing a car-engager platform to enhance the functionality and/or persistence of car t cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
WO2002020715A2 (en) * 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CA2544473C (en) 2003-11-03 2013-08-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
CN1256347C (zh) 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20060263368A1 (en) * 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Also Published As

Publication number Publication date
ZA201308597B (en) 2014-12-23
NZ617353A (en) 2015-01-30
EA201391546A1 (ru) 2014-02-28
WO2012143477A2 (en) 2012-10-26
SG193925A1 (en) 2013-11-29
JP2014513943A (ja) 2014-06-19
MX2013012242A (es) 2014-01-23
WO2012143477A3 (en) 2013-03-14
CA2832152A1 (en) 2012-10-26
PH12013501970A1 (en) 2014-01-06
US20140031283A1 (en) 2014-01-30
IL228731A0 (en) 2013-12-31
CN103562220A (zh) 2014-02-05
AU2012244654A1 (en) 2013-11-21
KR20140019828A (ko) 2014-02-17
BR112013025975A2 (pt) 2016-11-29
EP2699592A2 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
PH12014501083A1 (en) Anticancer fusion protein
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
PH12013500714A1 (en) Anticancer fusion protein
MX352796B (es) Proteina de fusion anticancerigena.
PH12013500050A1 (en) Anticancer fusion protein
PH12013501970A1 (en) Anticancer fusion protein
UA113712C2 (xx) Антитіло до fap і способи його застосування
MX2015004060A (es) 3-epimerasa.
MX383543B (es) Anticuerpo anti-calicreina-2 humanizado.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
WO2014057436A3 (en) Anticancer conjugate
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
BR112018015826A2 (pt) anticorpos monoclonais específicos egfl6 e métodos de seu uso
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
UA108911C2 (xx) Протираковий злитий протеїн
UA112522C2 (uk) Спосіб терапії злоякісної пухлини

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)